


SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round. The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More

Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing. The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta’s former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV… Read More

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors. The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC… Read More

Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics. The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More



In this contribution to the Fall 2026 issue of DDW, Jon Rees, Co-Founder and CEO of MitoRx, talks about the journey obesity treatments are taking and where the opportunities lie. Few areas of medicine have been reshaped as fast as the pharmaceutical treatment of obesity. Read More


The eBook explores the latest innovations in neuroscience drug discovery and how new approaches could revolutionise the treatment of these diseases.




This eBook explores how the mRNA platform has evolved since its use in Covid-19 vaccines, from the prevention of seasonal illnesses to personalised therapies for a range of diseases.

